HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hiroyuki Aburatani Selected Research

oncofetal antigens

7/2017Gastric Cancer With Primitive Enterocyte Phenotype: An Aggressive Subgroup of Intestinal-type Adenocarcinoma.
12/2005The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Hiroyuki Aburatani Research Topics

Disease

120Neoplasms (Cancer)
02/2022 - 01/2002
26Carcinogenesis
01/2020 - 01/2002
16Hepatocellular Carcinoma (Hepatoma)
10/2019 - 06/2002
13Neoplasm Metastasis (Metastasis)
01/2021 - 03/2003
12Carcinoma (Carcinomatosis)
01/2020 - 07/2002
12Stomach Neoplasms (Stomach Cancer)
11/2019 - 01/2002
12Glioma (Gliomas)
01/2019 - 06/2002
11Hypoxia (Hypoxemia)
11/2021 - 04/2007
9Fibrosis (Cirrhosis)
01/2022 - 12/2003
8Colorectal Neoplasms (Colorectal Cancer)
01/2019 - 01/2007
8Breast Neoplasms (Breast Cancer)
01/2018 - 12/2003
8Liver Neoplasms (Liver Cancer)
01/2018 - 06/2006
7Lung Neoplasms (Lung Cancer)
01/2022 - 03/2003
7Inflammation (Inflammations)
01/2021 - 09/2002
7Adenocarcinoma of Lung
10/2020 - 12/2005
7Leiomyosarcoma
03/2020 - 01/2011
7Adenocarcinoma
01/2020 - 10/2005
6Heart Failure
01/2022 - 12/2003
6Melanoma (Melanoma, Malignant)
01/2021 - 11/2004
6Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2020 - 03/2005
6Body Weight (Weight, Body)
11/2019 - 09/2002
6Glioblastoma (Glioblastoma Multiforme)
01/2019 - 01/2004
6Insulin Resistance
10/2012 - 12/2002
5Prostatic Neoplasms (Prostate Cancer)
02/2018 - 01/2009
5Colonic Neoplasms (Colon Cancer)
10/2014 - 08/2004
4Pancreatic Neoplasms (Pancreatic Cancer)
01/2020 - 01/2012
4Oligodendroglioma
01/2019 - 06/2002
4Bone Resorption
09/2013 - 06/2004
3Renal Cell Carcinoma (Grawitz Tumor)
01/2022 - 10/2007
3Down Syndrome (Down's Syndrome)
01/2021 - 11/2004
3Starvation
10/2019 - 05/2013
3Microsatellite Instability
04/2019 - 02/2012
3Squamous Cell Carcinoma (Epidermoid Carcinoma)
12/2018 - 01/2008
3Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2018 - 11/2012
3Epstein-Barr Virus Infections
08/2017 - 07/2002
3Leukemia
01/2016 - 06/2012
3Germ Cell and Embryonal Neoplasms (Germ Cell Tumor)
02/2014 - 09/2006
3Hypertrophy
12/2006 - 12/2003
2Dilated Cardiomyopathy (Cardiomyopathy, Congestive)
01/2022 - 10/2019

Drug/Important Bio-Agent (IBA)

38Proteins (Proteins, Gene)FDA Link
10/2018 - 02/2003
28DNA (Deoxyribonucleic Acid)IBA
02/2022 - 01/2003
21RNA (Ribonucleic Acid)IBA
02/2022 - 12/2003
17Biological ProductsIBA
03/2019 - 01/2002
14Biomarkers (Surrogate Marker)IBA
01/2020 - 04/2004
14OligonucleotidesIBA
12/2007 - 01/2002
13Messenger RNA (mRNA)IBA
01/2021 - 07/2002
13Transcription Factors (Transcription Factor)IBA
01/2021 - 02/2006
12Pharmaceutical PreparationsIBA
01/2021 - 11/2002
9AntigensIBA
12/2018 - 03/2005
9Histones (Histone)IBA
01/2018 - 01/2009
9ChromatinIBA
01/2018 - 02/2007
9GlypicansIBA
06/2009 - 02/2003
8Transforming Growth Factors (Transforming Growth Factor)IBA
01/2022 - 03/2009
8Monoclonal AntibodiesIBA
04/2015 - 12/2005
7Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
03/2020 - 11/2004
7ErbB Receptors (EGF Receptor)IBA
01/2020 - 04/2007
6Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
01/2020 - 01/2002
6Phosphotransferases (Kinase)IBA
11/2019 - 10/2007
6AndrogensIBA
02/2018 - 01/2009
6Androgen Receptors (Androgen Receptor)IBA
02/2018 - 01/2009
6Small Interfering RNA (siRNA)IBA
04/2017 - 04/2010
6LigandsIBA
11/2016 - 09/2002
6MucinsIBA
04/2015 - 05/2005
6Glucose (Dextrose)FDA LinkGeneric
11/2013 - 12/2002
6Transforming Growth Factor beta (TGF-beta)IBA
04/2009 - 12/2002
5Long Noncoding RNAIBA
01/2021 - 06/2013
5AntibodiesIBA
12/2018 - 04/2006
5Cadherins (E-Cadherin)IBA
09/2016 - 01/2002
4CytokinesIBA
01/2022 - 07/2002
4Triglycerides (Triacylglycerol)IBA
01/2020 - 02/2002
4Complementary DNA (cDNA)IBA
01/2012 - 03/2005
4alpha-Fetoproteins (alpha-Fetoprotein)IBA
04/2009 - 04/2004
4Insulin (Novolin)FDA Link
03/2007 - 12/2002
3(R)-2-(3-((benzoxazol-2-yl-d4 (3- (4- methoxyphenoxy- d7)propyl)amino)methyl)phenoxy) butanoic acidIBA
01/2022 - 01/2020
3Peptide Hydrolases (Proteases)FDA Link
01/2022 - 08/2004
3Telomerase (Telomerase Reverse Transcriptase)IBA
01/2021 - 08/2006
3Untranslated RNA (Noncoding RNA)IBA
01/2021 - 01/2016
3CalcineurinIBA
01/2021 - 11/2004
3Transforming Growth Factor-beta Type II ReceptorIBA
01/2020 - 04/2009
3NucleotidesIBA
04/2019 - 01/2011
3EpitopesIBA
12/2018 - 12/2005
3DecitabineFDA Link
01/2016 - 01/2010
3Protein Isoforms (Isoforms)IBA
01/2016 - 12/2006
3Hormones (Hormone)IBA
07/2014 - 01/2009
3TOR Serine-Threonine KinasesIBA
01/2014 - 01/2012
3CohesinsIBA
10/2013 - 02/2008
3Hypoxia-Inducible Factor 1IBA
06/2013 - 03/2009
3NF-kappa B (NF-kB)IBA
11/2012 - 06/2004
3Indicators and Reagents (Reagents)IBA
11/2010 - 12/2005
3beta CateninIBA
06/2010 - 02/2006
3Heparan Sulfate Proteoglycans (Heparan Sulfate Proteoglycan)IBA
06/2009 - 12/2005
3PPAR gammaIBA
03/2007 - 09/2002
3SaltsIBA
09/2006 - 12/2002
2Ribosomal RNAIBA
01/2022 - 11/2019
2Glutamine (L-Glutamine)FDA Link
01/2022 - 10/2019

Therapy/Procedure

29Therapeutics
01/2022 - 03/2005
7Immunotherapy
01/2022 - 03/2005
5Drug Therapy (Chemotherapy)
01/2017 - 06/2002
3Transplantation
11/2012 - 11/2010
3Lasers (Laser)
10/2012 - 01/2010